Characterization of the mucosal microbiota in patients with nodular lymphoid hyperplasia with concurrent irritable bowel syndrome compared to healthy controls.
Irritable bowel syndrome
Mucosal microbiota
Nodular lymphoid hyperplasia
Pathogen colonization
Quantitative real-time PCR
Terminal ileum biopsy
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
03
07
2022
accepted:
21
09
2022
pubmed:
1
11
2022
medline:
1
2
2023
entrez:
31
10
2022
Statut:
ppublish
Résumé
Nodular lymphoid hyperplasia (NLH) is known as a lymphoproliferative lesion in which multiple small nodules appear on the intestinal wall. It has been documented that patients who struggle with irritable bowel syndrome (IBS) are at greater risk of developing NLH. Here, we aimed to investigate the previously reported pathogens and the abundance of a selection of mucosal microbiota in IBS + NLH patients compared to IBS, and healthy controls. Terminal ileum biopsies were collected from 37 IBS + NLH, 37 IBS, and 29 healthy controls. Bacterial culture and PCR was performed to detect the presence of pathogens in biopsies. A qPCR assay was applied to assess the abundance of a selection of bacterial taxa. Totally, five bacterial isolates including two enteropathogenic and one enteroaggregative Escherichia coli (EPEC, EAEC), one enterotoxigenic Staphylococcus aureus (SEA), and one Yersinia enterocolitica strains were detected among the IBS + NLH cases. The relative abundance of Bacteroidetes and Streptococcus spp. in IBS + NLH patients was significantly less than IBS and healthy controls. Firmicutes, Pseudomonas spp., Haemophilus spp., and Campylobacter spp. were notably more abundant in IBS + NLH than in IBS patients. The abundance of Verrucomicrobia was higher in NLH + IBS than in healthy controls. Actinobacteria was also significantly more abundant among NLH + IBS patients than the controls. Our results demonstrated that mucosal microbiota composition in NLH + IBS patients slightly differs from that of IBS patients and healthy controls. Further research using large-scale cohorts are needed to enhance current understanding of the contribution of the mucosal microbiota to NLH pathogenesis with concurrent IBS.
Sections du résumé
BACKGROUND
BACKGROUND
Nodular lymphoid hyperplasia (NLH) is known as a lymphoproliferative lesion in which multiple small nodules appear on the intestinal wall. It has been documented that patients who struggle with irritable bowel syndrome (IBS) are at greater risk of developing NLH. Here, we aimed to investigate the previously reported pathogens and the abundance of a selection of mucosal microbiota in IBS + NLH patients compared to IBS, and healthy controls.
METHODS AND RESULTS
RESULTS
Terminal ileum biopsies were collected from 37 IBS + NLH, 37 IBS, and 29 healthy controls. Bacterial culture and PCR was performed to detect the presence of pathogens in biopsies. A qPCR assay was applied to assess the abundance of a selection of bacterial taxa. Totally, five bacterial isolates including two enteropathogenic and one enteroaggregative Escherichia coli (EPEC, EAEC), one enterotoxigenic Staphylococcus aureus (SEA), and one Yersinia enterocolitica strains were detected among the IBS + NLH cases. The relative abundance of Bacteroidetes and Streptococcus spp. in IBS + NLH patients was significantly less than IBS and healthy controls. Firmicutes, Pseudomonas spp., Haemophilus spp., and Campylobacter spp. were notably more abundant in IBS + NLH than in IBS patients. The abundance of Verrucomicrobia was higher in NLH + IBS than in healthy controls. Actinobacteria was also significantly more abundant among NLH + IBS patients than the controls.
CONCLUSION
CONCLUSIONS
Our results demonstrated that mucosal microbiota composition in NLH + IBS patients slightly differs from that of IBS patients and healthy controls. Further research using large-scale cohorts are needed to enhance current understanding of the contribution of the mucosal microbiota to NLH pathogenesis with concurrent IBS.
Identifiants
pubmed: 36315327
doi: 10.1007/s11033-022-07974-1
pii: 10.1007/s11033-022-07974-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
145-155Subventions
Organisme : Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
ID : RIGLD 1177
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Jørgensen PB, Fenton TM, Mörbe UM, Riis LB, Jakobsen HL, Nielsen OH, Agace WW (2021) Identification, isolation and analysis of human gut-associated lymphoid tissues. Nat Protoc 16(4):2051–2067
doi: 10.1038/s41596-020-00482-1
Rubio-Tapia A, Hernández-Calleros J, Trinidad-Hernández S, Uscanga L (2006) Clinical characteristics of a group of adults with nodular lymphoid hyperplasia: a single center experience. WJG 12(12):1945
Montazeri SA, Mahfoodh FH, Naybandi Atashi S, Sima AR, Saffar H, Radmard AR (2021) Nodular lymphoid hyperplasia of terminal ileum: how to avoid overdiagnosis of Crohn’s terminal ileitis in MR enterography? Abdom Radiol 46(5):1846–1854
doi: 10.1007/s00261-020-02866-z
Krauss E, Konturek P, Maiss J, Kressel J, Schulz U, Hahn E, Neurath M, Raithel M (2010) Clinical significance of lymphoid hyperplasia of the lower gastrointestinal tract. Endoscopy 42(04):334–337
doi: 10.1055/s-0029-1243936
Park KS, Ahn SH, Hwang JS, Cho KB, Chung WJ, Jang BK, Kang YN, Kwon JH, Kim YH (2008) A survey about irritable bowel syndrome in South Korea. Dig Dis Sci 53(3):704–711
doi: 10.1007/s10620-007-9930-1
Dyadyk OO, Snisarevskyi PP, Snisarevska TP (2021) Morphological features of cellular infiltration in the mucosa of large intestine in ulcerative colitis and irritable bowel syndrome. Wiad Lek 74(1):57–63
doi: 10.36740/WLek202101111
Kagueyama FMN, Nicoli FM, Bonatto MW, Orso IRB (2014) Importance of biopsies and histological evaluation in patients with chronic diarrhea and normal colonoscopies. ABCD 27:184–187
Marzollo A, Bresolin S, Colavito D, Cani A, Gaio P, Bosa L, Mescoli C, Rossini L, Barzaghi F, Perilongo G (2021) Case report: intestinal nodular lymphoid hyperplasia as first manifestation of activated PI3Kδ syndrome due to a novel PIK3CD variant. Front Pediat 9:703056
doi: 10.3389/fped.2021.703056
Lin R, Lu H, Zhou G, Wei Q, Liu Z (2017) Clinicopathological and ileocolonoscopic characteristics in patients with nodular lymphoid hyperplasia in the terminal ileum. Int J Med Sci 14(8):750
doi: 10.7150/ijms.19480
Meglio LD, Carucci L, Berni Canani R (2022) Immunodeficiency disorders resulting in malabsorption. J Pediatr Gastroenterol Nutr 495–511
Piscaglia AC, Laterza L, Cesario V, Gerardi V, Landi R, Lopetuso LR, Calò G, Fabbretti G, Brisigotti M, Stefanelli ML (2016) Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome? WJG 22(46):10198
Kamada N, Seo S-U, Chen GY, Núñez G (2013) Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immun 13(5):321–335
doi: 10.1038/nri3430
Monsanto P, Lérias C, Almeida N, Lopes S, Cabral J, Figueiredo P, Silva M, Julião M, Gouveia H, Sofia C (2012) Intestinal nodular lymphoid hyperplasia and extraintestinal lymphoma–a rare association. Acta Gastroenterol Belg 75(2):260–262
Oświęcimska J, Szymlak A, Roczniak W, Girczys-Połedniok K, Kwiecień J (2017) New insights into the pathogenesis and treatment of irritable bowel syndrome. Adv Med Sci 62(1):17–30
doi: 10.1016/j.advms.2016.11.001
Pérez-Roldán F, Mate-Valdezate A, Villafáñez-García M, Carro PG, Huidobro ML (2008) Nodular lymphoid hyperplasia by. Giardia lamblia Endoscopy 40(02):E116–E117
doi: 10.1055/s-2007-995398
Khuroo MS, Khuroo NS, Khuroo MS (2011) Diffuse duodenal nodular lymphoid hyperplasia: a large cohort of patients etiologically related to Helicobacter pylori infection. BMC Gastroenterol 11(1):1–12
doi: 10.1186/1471-230X-11-36
Albuquerque A (2014) Nodular lymphoid hyperplasia in the gastrointestinal tract in adult patients: A review. WJGE 6(11):534
doi: 10.4253/wjge.v6.i11.534
Hou K, Wu Z-X, Chen X-Y, Wang J-Q, Zhang D, Xiao C, Zhu D, Koya JB, Wei L, Li J (2022) Microbiota in health and diseases. Signal Transduct Target Ther 7(1):1–28
Fan Y, Pedersen O (2021) Gut microbiota in human metabolic health and disease. Nat Rev Microbiol 19(1):55–71
doi: 10.1038/s41579-020-0433-9
Denny JE, Powell WL, Schmidt NW (2016) Local and long-distance calling: conversations between the gut microbiota and intra-and extra-gastrointestinal tract infections. Front Cell Infect Microbiol 6:41
doi: 10.3389/fcimb.2016.00041
Manichanh C, Borruel N, Casellas F, Guarner F (2012) The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol 9(10):599–608
doi: 10.1038/nrgastro.2012.152
Han L, Zhao L, Zhou Y, Yang C, Xiong T, Lu L, Deng Y, Luo W, Chen Y, Qiu Q (2022) Altered metabolome and microbiome features provide clues in understanding irritable bowel syndrome and depression comorbidity. ISME J 16(4):983–996
doi: 10.1038/s41396-021-01123-5
Black CJ, Ford AC (2020) Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol 17(8):473–486
doi: 10.1038/s41575-020-0286-8
Saffouri GB, Shields-Cutler RR, Chen J, Yang Y, Lekatz HR, Hale VL, Cho JM, Battaglioli EJ, Bhattarai Y, Thompson KJ (2019) Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders. Nat Commun 10(1):1–11
doi: 10.1038/s41467-019-09964-7
Jiang Q-L, Lu Y, Zhang M-J, Cui Z-Y, Pei Z-M, Li W-H, Lu L-G, Wang J-J, Lu Y-Y (2022) Mucosal bacterial dysbiosis in patients with nodular lymphoid hyperplasia in the terminal ileum. WJG 28(8):811
doi: 10.3748/wjg.v28.i8.811
Zuo T, Kamm MA, Colombel J-F, Ng SC (2018) Urbanization and the gut microbiota in health and inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 15(7):440–452
doi: 10.1038/s41575-018-0003-z
Azimirad M, Krutova M, Balaii H, Kodori M, Shahrokh S, Azizi O, Yadegar A, Aghdaei HA, Zali MR (2020) Coexistence of Clostridioides difficile and Staphylococcus aureus in gut of Iranian outpatients with underlying inflammatory bowel disease. Anaerobe 61:102113
doi: 10.1016/j.anaerobe.2019.102113
Cunningham SA, Sloan LM, Nyre LM, Vetter EA, Mandrekar J, Patel R (2010) Three-hour molecular detection of Campylobacter, Salmonella, Yersinia, and Shigella species in feces with accuracy as high as that of culture. JCM 48(8):2929–2933
Razaghi M, Tajeddin E, Ganji L, Alebouyeh M, Alizadeh AHM, Sadeghi A, Zali MR (2017) Colonization, resistance to bile, and virulence properties of Escherichia coli strains: unusual characteristics associated with biliary tract diseases. Microb Pathog 111:262–268
doi: 10.1016/j.micpath.2017.08.043
Rashidan M, Azimirad M, Alebouyeh M, Ghobakhlou M, Aghdaei HA, Zali MR (2018) Detection of B. Fragilis group and diversity of bft enterotoxin and antibiotic resistance markers cepa, cfia and nim among intestinal Bacteroides fragilis strains in patients with inflammatory bowel disease. Anaerobe 50:93–100
doi: 10.1016/j.anaerobe.2018.02.005
Binda C, Lopetuso LR, Rizzatti G, Gibiino G, Cennamo V, Gasbarrini A (2018) Actinobacteria: a relevant minority for the maintenance of gut homeostasis. Dig Liver Dis 50(5):421–428
doi: 10.1016/j.dld.2018.02.012
Lo Presti A, Zorzi F, Del Chierico F, Altomare A, Cocca S, Avola A, De Biasio F, Russo A, Cella E, Reddel S (2019) Fecal and mucosal microbiota profiling in irritable bowel syndrome and inflammatory bowel disease. Front Microbiol 10:1655
doi: 10.3389/fmicb.2019.01655
Van Schewick CM, Lowe DM, Burns SO, Workman S, Symes A, Guzman D, Moreira F, Watkins J, Clark I, Grimbacher B (2022) Bowel Histology of CVID Patients Reveals Distinct Patterns of Mucosal Inflammation. J Clin Immunol 42(1):46–59
doi: 10.1007/s10875-021-01104-5
Naseri K, Dabiri H, Rostami-Nejad M, Yadegar A, Houri H, Olfatifar M, Sadeghi A, Saadati S, Ciacci C, Iovino P (2021) Influence of low FODMAP-gluten free diet on gut microbiota alterations and symptom severity in Iranian patients with irritable bowel syndrome. BMC Gastroenterol 21(1):1–14
doi: 10.1186/s12876-021-01868-5
Ostadmohammadi S, Azimirad M, Houri H, Naseri K, Javanmard E, Mirjalali H, Yadegar A, Sadeghi A, Asadzadeh Aghdaei H, Zali MR (2021) Characterization of the gut microbiota in patients with primary sclerosing cholangitis compared to inflammatory bowel disease and healthy controls. Mol Biol Rep 48(7):5519–5529
doi: 10.1007/s11033-021-06567-8
Dupont AW, dupont HL (2011) The intestinal microbiota and chronic disorders of the gut. Nat Rev Gastroenterol Hepatol 8(9):523–531
doi: 10.1038/nrgastro.2011.133
Grover M (2014) Role of gut pathogens in development of irritable bowel syndromeindian. J Med Res 139(1):11
Balemans D, Mondelaers S, Cibert-Goton V, Stakenborg N, Aguilera-Lizarraga J, Dooley J, Liston A, Bulmer D, Vanden Berghe P, Boeckxstaens G (2017) Evidence for long-term sensitization of the bowel in patients with post-infectious-IBS. Sci Rep 7(1):1–11
doi: 10.1038/s41598-017-12618-7
Barbara G, Cremon C, Pallotti F, De Giorgio R, Stanghellini V, Corinaldesi R (2009) Postinfectious irritable bowel syndrome. J Pediatr Gastroenterol Nutr 48:S95–S97
doi: 10.1097/MPG.0b013e3181a15e2e
Peters S, Pascoe B, Wu Z, Bayliss SC, Zeng X, Edwinson A, Veerabadhran-Gurunathan S, Jawahir S, Calland JK, Mourkas E (2021) Campylobacter jejuni genotypes are associated with post-infection irritable bowel syndrome in humans. Commun Biol 4(1):1–17
doi: 10.1038/s42003-021-02554-8
Ganji L, Shirazi MH, Ebrahimi-Daryani N, Eslami P, Rahbar M, Zali MR, Alebouyeh M (2022) Carriage of cdtb encoding Campylobacter spp., Salmonella enterica, and Yersinia entercolitica in patients with gastroenteritis and irritable bowel syndrome. Dig Dis Sci 2022:1–7
Youn YH, Kim HC, Lim HC, Park JJ, Kim J-H, Park H (2016) Long-term clinical course of post-infectious irritable bowel syndrome after shigellosis: a 10-year follow-up study. J Neurogastroenterol Motil 22(3):490
doi: 10.5056/jnm15157
Rinttilä T, Lyra A, Krogius-Kurikka L, Palva A (2011) Real-time PCR analysis of enteric pathogens from fecal samples of irritable bowel syndrome subjects. Gut Pathog 3(1):1–9
doi: 10.1186/1757-4749-3-6
Ennaifer R, Slama SB, Romdhane H, Bayar R, Cheikh M, Nejma HB, Mestiri H, Hadj NB (2015) Nodular hyperplasia of the gastrointestinal tract after liver transplantation: role of immunosuppressive therapy? a case report. Transpl Proc 47(3):820–822
doi: 10.1016/j.transproceed.2015.02.009
Si J-M, Yu Y-C, Fan Y-J, Chen S-J (2004) Intestinal microecology and quality of life in irritable bowel syndrome patients. WJG 10(12):1802
doi: 10.3748/wjg.v10.i12.1802
Su T, Liu R, Lee A, Long Y, Du L, Lai S, Chen X, Wang L, Si J, Owyang C (2018) Altered intestinal microbiota with increased abundance of Prevotella is associated with high risk of diarrhea-predominant irritable bowel syndrome. Gastroenterol Res Pract 6961783
Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterol 133(1):24–33
doi: 10.1053/j.gastro.2007.04.005
Matsumoto H, Shiotani A, Katsumata R, Fukushima S, Handa Y, Osawa M, Murao T, Handa O, Umegaki E, Inoue R (2021) Mucosa-associated microbiota in patients with irritable bowel syndrome: a comparison of subtypes. Digest 102(1):49–56
doi: 10.1159/000512167
Kerckhoffs AP, Ben-Amor K, Samsom M, van der Rest ME, de Vogel J, Knol J, Akkermans LM (2011) Molecular analysis of faecal and duodenal samples reveals significantly higher prevalence and numbers of Pseudomonas aeruginosa in irritable bowel syndrome. JMM 60(2):236–245